Exploration of the therapeutic aspects of Lck: A kinase target in inflammatory mediated pathological conditions.

[1]  W. Fiers,et al.  Overlapping patterns of activation of human endothelial cells by interleukin 1, tumor necrosis factor, and immune interferon. , 1986, Journal of immunology.

[2]  R. Perlmutter,et al.  Interaction of the unique N-terminal region of tyrosine kinase p56 lck with cytoplasmic domains of CD4 and CD8 is mediated by cysteine motifs , 1990, Cell.

[3]  T. Pawson,et al.  Structural requirements for enhancement of T-cell responsiveness by the lymphocyte-specific tyrosine protein kinase p56lck , 1992, Molecular and cellular biology.

[4]  A. Weiss.  T cell antigen receptor signal transduction: A tale of tails and cytoplasmic protein-tyrosine kinases , 1993, Cell.

[5]  J. Kuriyan,et al.  Binding of a high affinity phosphotyrosyl peptide to the Src SH2 domain: Crystal structures of the complexed and peptide-free forms , 1993, Cell.

[6]  T. Roberts,et al.  Lck Unique Domain Influences Lck Specificity and Biological Function (*) , 1995, The Journal of Biological Chemistry.

[7]  A. Weiss,et al.  αβ T Cell Development Is Abolished in Mice Lacking Both Lck and Fyn Protein Tyrosine Kinases , 1996 .

[8]  H. Hanafusa,et al.  Detection of a Physical and Functional Interaction between Csk and Lck Which Involves the SH2 Domain of Csk and Is Mediated by Autophosphorylation of Lck on Tyrosine 394 (*) , 1996, The Journal of Biological Chemistry.

[9]  B. Druker,et al.  Identification of the Src family kinases, Lck and Fgr in platelets. Their tyrosine phosphorylation status and subcellular distribution compared with other Src family members. , 1997, Arteriosclerosis, thrombosis, and vascular biology.

[10]  E. Zandi,et al.  AP-1 function and regulation. , 1997, Current opinion in cell biology.

[11]  S. Hubbard,et al.  Protein tyrosine kinase structure and function. , 2000, Annual review of biochemistry.

[12]  S. Takahashi,et al.  ERM-dependent movement of CD43 defines a novel protein complex distal to the immunological synapse. , 2001, Immunity.

[13]  S. Ratnofsky,et al.  Lck inhibitors as a therapeutic approach to autoimmune disease and transplant rejection. , 2001, Current opinion in investigational drugs.

[14]  B. Malissen,et al.  Tyrosine 315 determines optimal recruitment of ZAP‐70 to the T cell antigen receptor , 2002, European journal of immunology.

[15]  R. Geahlen,et al.  Characterization of the in Vivo Sites of Serine Phosphorylation on Lck Identifying Serine 59 as a Site of Mitotic Phosphorylation* , 2002, The Journal of Biological Chemistry.

[16]  P. Rothman,et al.  JAK-STAT signaling in asthma. , 2002, The Journal of clinical investigation.

[17]  Nunzio Bottini,et al.  A functional variant of lymphoid tyrosine phosphatase is associated with type I diabetes , 2004, Nature Genetics.

[18]  S. Ratnofsky,et al.  A-420983: a potent, orally active inhibitor of lck with efficacy in a model of transplant rejection. , 2004, Bioorganic & medicinal chemistry letters.

[19]  J. Martin-Villa,et al.  Higher proliferative capacity of T lymphocytes from patients with Crohn disease than from ulcerative colitis is disclosed by use of Herpesvirus saimiri-transformed T-cell lines , 2004, Scandinavian journal of gastroenterology.

[20]  Arthur Weiss,et al.  Function of the Src-family kinases, Lck and Fyn, in T-cell development and activation , 2004, Oncogene.

[21]  X. Bustelo,et al.  Inverted signaling hierarchy between RAS and RAC in T-lymphocytes , 2004, Oncogene.

[22]  Dong-hai Wang,et al.  Phosphorylation of CARMA1 plays a critical role in T Cell receptor-mediated NF-kappaB activation. , 2005, Immunity.

[23]  F. Macian,et al.  NFAT proteins: key regulators of T-cell development and function , 2005, Nature Reviews Immunology.

[24]  W. Wong,et al.  Inhibitors of the tyrosine kinase signaling cascade for asthma. , 2005, Current opinion in pharmacology.

[25]  Shalini Jain,et al.  Hypoxia Regulates Cross-talk between Syk and Lck Leading to Breast Cancer Progression and Angiogenesis* , 2006, Journal of Biological Chemistry.

[26]  E. Suchanek,et al.  The development of novel 1,2-dihydro-pyrimido[4,5-c]pyridazine based inhibitors of lymphocyte specific kinase (Lck). , 2006, Bioorganic & medicinal chemistry letters.

[27]  D. Borhani,et al.  Discovery of A-770041, a src-family selective orally active lck inhibitor that prevents organ allograft rejection. , 2006, Bioorganic & medicinal chemistry letters.

[28]  T. Smithgall,et al.  Small molecule inhibitors of Lck: the search for specificity within a kinase family. , 2008, Mini reviews in medicinal chemistry.

[29]  Jayajit Das,et al.  Digital Signaling and Hysteresis Characterize Ras Activation in Lymphoid Cells , 2009, Cell.

[30]  G. Koretzky,et al.  T cell activation. , 2009, Annual review of immunology.

[31]  B. Kaplan,et al.  Recent Developments in Kidney Transplantation—A Critical Assessment , 2009, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[32]  D. Robinson,et al.  The role of the T cell in asthma. , 2010, The Journal of allergy and clinical immunology.

[33]  H. Amada,et al.  Ring-fused pyrazole derivatives as potent inhibitors of lymphocyte-specific kinase (Lck): Structure, synthesis, and SAR. , 2010, Bioorganic & medicinal chemistry letters.

[34]  P. Furet,et al.  New pyrazolo[1,5a]pyrimidines as orally active inhibitors of Lck. , 2010, Bioorganic & medicinal chemistry letters.

[35]  F. Zhong,et al.  Inhibition of Lck enhances glucocorticoid sensitivity and apoptosis in lymphoid cell lines and in chronic lymphocytic leukemia , 2010, Cell Death and Differentiation.

[36]  P. Stein,et al.  Lck Mediates Th2 Differentiation through Effects on T-bet and GATA-3 , 2010, The Journal of Immunology.

[37]  R. Joseph,et al.  T-cell signaling regulated by the Tec family kinase, Itk. , 2010, Cold Spring Harbor perspectives in biology.

[38]  Eilon Sherman,et al.  The LAT story: a tale of cooperativity, coordination, and choreography. , 2010, Cold Spring Harbor perspectives in biology.

[39]  O. Hrusak,et al.  ETV6/RUNX1 (TEL/AML1) is a frequent prenatal first hit in childhood leukemia. , 2011, Blood.

[40]  R. Zamoyska,et al.  Mislocalization of Lck impairs thymocyte differentiation and can promote development of thymomas. , 2011, Blood.

[41]  A. Shaughnessy.  Monoclonal antibodies: magic bullets with a hefty price tag , 2012, BMJ : British Medical Journal.

[42]  F. J. Monje,et al.  Alzheimer’s disease risk factor lymphocyte-specific protein tyrosine kinase regulates long-term synaptic strengthening, spatial learning and memory , 2012, Cellular and Molecular Life Sciences.

[43]  John Kuriyan,et al.  Structural Basis for Activation of ZAP-70 by Phosphorylation of the SH2-Kinase Linker , 2013, Molecular and Cellular Biology.

[44]  G. Mann,et al.  Sequestosome1/p62: a regulator of redox-sensitive voltage-activated potassium channels, arterial remodeling, inflammation, and neurite outgrowth. , 2013, Free radical biology & medicine.

[45]  J. Slupsky,et al.  LCK Is an Important Mediator of B-Cell Receptor Signaling in Chronic Lymphocytic Leukemia Cells , 2013, Molecular Cancer Research.

[46]  B. Ryffel,et al.  Antifibrotic and Anti-inflammatory Activity of the Tyrosine Kinase Inhibitor Nintedanib in Experimental Models of Lung Fibrosis , 2014, The Journal of Pharmacology and Experimental Therapeutics.

[47]  Arup K Chakraborty,et al.  Insights into the initiation of TCR signaling , 2014, Nature Immunology.

[48]  S. Shichijo,et al.  Identification of novel Lck‐derived T helper epitope long peptides applicable for HLA‐A2+ cancer patients as cancer vaccine , 2015, Cancer science.

[49]  P. Hawkins,et al.  PI3K signalling in inflammation. , 2015, Biochimica et biophysica acta.

[50]  Anita Patel,et al.  Tumour necrosis factor inhibitors versus combination intensive therapy with conventional disease modifying anti-rheumatic drugs in established rheumatoid arthritis: TACIT non-inferiority randomised controlled trial , 2015, BMJ : British Medical Journal.

[51]  In‐San Kim,et al.  βig-h3 Represses T-Cell Activation in Type 1 Diabetes , 2015, Diabetes.

[52]  Yonghua Zheng,et al.  The effect of siRNA-mediated lymphocyte-specific protein tyrosine kinase (Lck) inhibition on pulmonary inflammation in a mouse model of asthma. , 2015, International journal of clinical and experimental medicine.

[53]  V. Gallo,et al.  Severe combined immunodeficiency—an update , 2015, Annals of the New York Academy of Sciences.

[54]  P. Vandenabeele,et al.  Necroptosis and its role in inflammation , 2015, Nature.

[55]  H. Thomas,et al.  Protein tyrosine phosphatases: molecular switches in metabolism and diabetes , 2015, Trends in Endocrinology & Metabolism.

[56]  M. Abbaszadegan,et al.  Idiopathic lymphocytopenia , 2015, Current opinion in hematology.

[57]  P. Singh,et al.  Kinases inhibitors in lung cancer: From benchside to bedside. , 2016, Biochimica et biophysica acta.

[58]  Stacey D. Finley,et al.  Predictive Model of Lymphocyte-Specific Protein Tyrosine Kinase (LCK) Autoregulation , 2016, Cellular and Molecular Bioengineering.

[59]  Wenshuai He,et al.  Lck Inhibits Heat Shock Protein 65–Mediated Reverse Cholesterol Transport in T Cells , 2016, The Journal of Immunology.

[60]  A. Chakraborty,et al.  Phosphorylation of a Tyrosine Residue on Zap70 by Lck and Its Subsequent Binding via an SH2 Domain May Be a Key Gatekeeper of T Cell Receptor Signaling In Vivo , 2016, Molecular and Cellular Biology.

[61]  S. Zhuang,et al.  Src family kinases in chronic kidney disease. , 2017, American journal of physiology. Renal physiology.

[62]  J. Kuriyan,et al.  A Phosphosite within the SH2 Domain of Lck Regulates Its Activation by CD45. , 2017, Molecular cell.

[63]  L. Simeoni.  Lck activation: puzzling the pieces together , 2017, Oncotarget.

[64]  A. Pettitt,et al.  Lck is a relevant target in chronic lymphocytic leukaemia cells whose expression variance is unrelated to disease outcome , 2017, Scientific Reports.

[65]  S. Nedospasov,et al.  Low level of Lck kinase in Th2 cells limits expression of CD4 co-receptor and S73 phosphorylation of transcription factor c-Jun , 2017, Scientific Reports.

[66]  K. Famulski,et al.  Comprehensive Analysis of Transcript Changes Associated With Allograft Rejection: Combining Universal and Selective Features , 2017, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[67]  Seahyoung Lee,et al.  7‐cyclopentyl‐5‐(4‐phenoxyphenyl)−7H‐pyrrolo[2,3‐d] pyrimidin‐4‐ylamine inhibits the proliferation and migration of vascular smooth muscle cells by suppressing ERK and Akt pathways , 2017, European journal of pharmacology.

[68]  M. Parkes,et al.  Mechanistic Sharing Between NK Cells in ABMR and Effector T Cells in TCMR , 2018, American journal of transplantation : official journal of the American Society of Transplantation and the American Society of Transplant Surgeons.

[69]  J. Kuriyan,et al.  Lck promotes Zap70-dependent LAT phosphorylation by bridging Zap70 to LAT , 2018, Nature Immunology.

[70]  Dana M Previte,et al.  Reactive Oxygen Species and Their Implications on CD4+ T Cells in Type 1 Diabetes. , 2017, Antioxidants & redox signaling.

[71]  L. Jia,et al.  LCK as a Potential Therapeutic Target for Acute Rejection after Kidney Transplantation: A Bioinformatics Clue , 2018, Journal of immunology research.